Tacrine

Tacrine is an effective oral acetylcholine (AChE) inhibitor (IC50 = 109 nM) and also acts as an active substrate for CYP1A2. Tacrine can restore cognitive dysfunction in elderly rats. Tacrine can cause liver toxicity and is used in research related to Alzheimer's disease[1][2][3][4].

Product Specifications

CAS Number

[321-64-2]

UNSPSC

12352005

Hazard Statement

H301, H311, H315, H319, H331, H335, H351

Target

Cholinesterase (ChE)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tacrine.html

Purity

99.75

Solubility

DMSO : ≥ 100 mg/mL

Smiles

NC1=C2CCCCC2=NC3=CC=CC=C31

Molecular Formula

C13H14N2

Molecular Weight

198.27

Precautions

H301, H311, H315, H319, H331, H335, H351

References & Citations

[1]Patocka J, et al. Possible role of hydroxylated metabolites of tacrine in drug toxicity and therapy of Alzheimer's disease. Curr Drug Metab. 2008;9 (4) :332-335.|[2]Bhatt S, et al. Assessment of the CYP1A2 Inhibition-Mediated Drug Interaction Potential for Pinocembrin Using In Silico, In Vitro, and In Vivo Approaches. ACS Omega. 2022;7 (23) :20321-20331. Published 2022 Jun 2.|[3]Romero A, et al. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2013;23 (7) :1916-1922.|[4]C Scali, et al. Tacrine administration enhances extracellular acetylcholine in vivo and restores the cognitive impairment in aged rats. Pharmacol Res. 1997 Dec;36 (6) :463-9.